KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Royalty Pharma (RPRX) Other Operating Expenses: 2019-2025

Historic Other Operating Expenses for Royalty Pharma (RPRX) over the last 7 years, with Sep 2025 value amounting to $12.9 million.

  • Royalty Pharma's Other Operating Expenses rose 105.67% to $12.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$61.6 million, marking a year-over-year decrease of 112.52%. This contributed to the annual value of $732.5 million for FY2024, which is 30.64% up from last year.
  • Latest data reveals that Royalty Pharma reported Other Operating Expenses of $12.9 million as of Q3 2025, which was up 111.58% from -$111.4 million recorded in Q2 2025.
  • Over the past 5 years, Royalty Pharma's Other Operating Expenses peaked at $924.7 million during Q4 2022, and registered a low of -$238.0 million during Q2 2021.
  • Over the past 3 years, Royalty Pharma's median Other Operating Expenses value was $118.8 million (recorded in 2023), while the average stood at $97.0 million.
  • Data for Royalty Pharma's Other Operating Expenses shows a peak YoY increase of 613.05% (in 2021) and a maximum YoY decrease of 549.02% (in 2021) over the last 5 years.
  • Quarterly analysis of 5 years shows Royalty Pharma's Other Operating Expenses stood at $272.3 million in 2021, then skyrocketed by 239.55% to $924.7 million in 2022, then plummeted by 108.27% to -$76.5 million in 2023, then skyrocketed by 314.39% to $164.0 million in 2024, then skyrocketed by 105.67% to $12.9 million in 2025.
  • Its Other Operating Expenses was $12.9 million in Q3 2025, compared to -$111.4 million in Q2 2025 and -$127.1 million in Q1 2025.